2007
DOI: 10.1007/s00280-007-0592-7
|View full text |Cite
|
Sign up to set email alerts
|

Phase II study of rubitecan in recurrent or metastatic head and neck cancer

Abstract: We conclude that rubitecan is not effective as a single-agent in recurrent or metastatic head and neck cancer with the doses and schedule used in this study.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2009
2009
2024
2024

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
references
References 18 publications
0
0
0
Order By: Relevance